Final results of the ReoPro readministration registry
- 15 April 2004
- journal article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 93 (8), 979-984
- https://doi.org/10.1016/j.amjcard.2003.12.051
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial InfarctionCirculation, 2003
- Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial InfarctionThe New England Journal of Medicine, 2001
- Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarctionJournal of the American College of Cardiology, 2000
- Abciximab readministration: A single-operator community-hospital experienceCatheterization and Cardiovascular Interventions, 1999
- Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 1998
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Safe use of platelet GP IIb/IIIa inhibitorsAmerican Heart Journal, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationThe New England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyThe New England Journal of Medicine, 1994